18.58
-0.81 (-4.18%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Omeros Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.5 |
| Price Volatility | -4.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.25 |
|
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.40% |
| % Held by Institutions | 47.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ingalls & Snyder Llc | 30 Jun 2026 | 3,659,523 |
| Kotler Kevin | 31 Dec 2025 | 905,635 |
| Rock Springs Capital Management Lp | 30 Jun 2026 | 718,499 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CANCELMO PETER B | - | 18.70 | -50,000 | -935,000 |
| HANISH ARNOLD C | - | 19.25 | -10,000 | -192,500 |
| Aggregate Net Quantity | -60,000 | |||
| Aggregate Net Value ($) | -1,127,500 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 18.88 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CANCELMO PETER B | Officer | 31 Aug 2026 | Sell (-) | 25,000 | 18.79 | 469,750 |
| CANCELMO PETER B | Officer | 31 Aug 2026 | Option execute | 25,000 | - | - |
| CANCELMO PETER B | Officer | 28 Aug 2026 | Sell (-) | 25,000 | 18.61 | 465,250 |
| CANCELMO PETER B | Officer | 28 Aug 2026 | Option execute | 25,000 | - | - |
| HANISH ARNOLD C | Director | 27 Aug 2026 | Sell (-) | 10,000 | 19.25 | 192,500 |
| HANISH ARNOLD C | Director | 27 Aug 2026 | Option execute | 10,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |